Literature DB >> 30933921

Reductions in length of stay, narcotics use, and pain following implementation of an enhanced recovery after surgery program for 1- to 3-level lumbar fusion surgery.

G Damian Brusko1, John Paul G Kolcun1, Julie A Heger1, Allan D Levi1, Glen R Manzano1, Karthik Madhavan1, Timur Urakov1, Richard H Epstein2, Michael Y Wang1.   

Abstract

OBJECTIVELumbar fusion is typically associated with high degrees of pain and immobility. The implementation of an enhanced recovery after surgery (ERAS) approach has been successful in speeding the recovery after other surgical procedures. In this paper, the authors examined the results of early implementation of ERAS for lumbar fusion.METHODSBeginning in March 2018 at the authors' institution, all patients undergoing posterior, 1- to 3-level lumbar fusion surgery by any of 3 spine surgeons received an intraoperative injection of liposomal bupivacaine, immediate single postoperative infusion of 1-g intravenous acetaminophen, and daily postoperative visits from the authors' multidisciplinary ERAS care team. Non-English- or non-Spanish-speaking patients and those undergoing nonelective or staged procedures were excluded. Reviews of medical records were conducted for the ERAS cohort of 57 patients and a comparison group of 40 patients who underwent the same procedures during the 6 months before implementation.RESULTSGroups did not differ significantly with regard to sex, age, or BMI (all p > 0.05). Length of stay was significantly shorter in the ERAS cohort than in the control cohort (2.9 days vs 3.8 days; p = 0.01). Patients in the ERAS group consumed significantly less oxycodone-acetaminophen than the controls on postoperative day (POD) 0 (408.0 mg vs 1094.7 mg; p = 0.0004), POD 1 (1320.0 mg vs 1708.4 mg; p = 0.04), and POD 3 (1500.1 mg vs 2105.4 mg; p = 0.03). Postoperative pain scores recorded by the physical therapy and occupational therapy teams and nursing staff each day were lower in the ERAS cohort than in controls, with POD 1 achieving significance (4.2 vs 6.0; p = 0.006). The total amount of meperidine (8.8 mg vs 44.7 mg; p = 0.003) consumed was also significantly decreased in the ERAS group, as was ondansetron (2.8 mg vs 6.0 mg; p = 0.02). Distance ambulated on each POD was farther in the ERAS cohort, with ambulation on POD 1 (109.4 ft vs 41.4 ft; p = 0.002) achieving significance.CONCLUSIONSIn this very initial implementation of the first phase of an ERAS program for short-segment lumbar fusion, the authors were able to demonstrate substantial positive effects on the early recovery process. Importantly, these effects were not surgeon-specific and could be generalized across surgeons with disparate technical predilections. The authors plan additional iterations to their ERAS protocols for continued quality improvements.

Entities:  

Keywords:  ERAS; ERAS = enhanced recovery after surgery; Exparel; LOS = length of stay; MIS = minimally invasive surgery; POD = postoperative day; PT/OT = physical therapy and occupational therapy; cost; enhanced recovery after surgery; fast-track surgery; length of stay; lumbar fusion; outcomes; pain control; quality

Mesh:

Substances:

Year:  2019        PMID: 30933921     DOI: 10.3171/2019.1.FOCUS18692

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  18 in total

1.  The University of Miami spine surgery ERAS protocol: a review of our journey.

Authors:  Meng Huang; G Damian Brusko; Peter A Borowsky; John Paul G Kolcun; Julie A Heger; Richard H Epstein; Jay Grossman; Michael Y Wang
Journal:  J Spine Surg       Date:  2020-01

2.  Liposomal bupivacaine in posterior spine surgery: A piece of the puzzle for postoperative pain.

Authors:  D Alex Forrester; Harrison Miner; Cameron Shirazi; Niranjan Kavadi
Journal:  J Orthop       Date:  2022-07-12

3.  Experiences of Patients Taking Conditioned Open-Label Placebos for Reduction of Postoperative Pain and Opioid Exposure After Spine Surgery.

Authors:  Valerie Hruschak; K Mikayla Flowers; Megan Patton; Victoria Merchantz; Emily Schwartz; Robert Edwards; Ted Kaptchuk; James Kang; Michelle Dossett; Kristin Schreiber
Journal:  Int J Behav Med       Date:  2022-08-01

4.  Model-Based Computational Analysis on the Effectiveness of Enhanced Recovery after Surgery in the Operating Room with Nursing.

Authors:  Wenji Li; Shu Huang; Yong Xie; Guanyu Chen; Jun Yuan; Yun Yang
Journal:  Front Surg       Date:  2022-05-18

5.  Enhanced recovery after surgery (ERAS) improves return of physiological function in frail patients undergoing one- to two-level TLIFs: an observational retrospective cohort study.

Authors:  Ken Porche; Sandra Yan; Basma Mohamed; Cynthia Garvan; Ronny Samra; Kaitlyn Melnick; Sasha Vaziri; Christoph Seubert; Matthew Decker; Adam Polifka; Daniel J Hoh
Journal:  Spine J       Date:  2022-04-18       Impact factor: 4.297

Review 6.  Endoscopic transforaminal lumbar interbody fusion without general anesthesia: technical innovations and outcomes.

Authors:  John Paul G Kolcun; G Damian Brusko; Michael Y Wang
Journal:  Ann Transl Med       Date:  2019-09

7.  Accelerometry Data Delineate Phases of Recovery and Supplement Patient-Reported Outcome Measures Following Lumbar Laminectomy.

Authors:  Dennis M Bienstock; Dhruv Shankar; Jinseong Kim; Michael Gao; Komal Srivastava; Wesley H Bronson; Saad B Chaudhary; Jashvant Poeran; James C Iatridis; Andrew C Hecht
Journal:  World Neurosurg       Date:  2022-01-29       Impact factor: 2.210

Review 8.  What Is the Evidence for Early Mobilisation in Elective Spine Surgery? A Narrative Review.

Authors:  Louise C Burgess; Thomas W Wainwright
Journal:  Healthcare (Basel)       Date:  2019-07-18

9.  The Endoscopic Approach to Lumbar Discectomy, Fusion, and Enhanced Recovery: A Review.

Authors:  Jason I Liounakos; Michael Y Wang
Journal:  Global Spine J       Date:  2020-05-28

10.  Bupivacaine Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine Administered After Cesarean Birth.

Authors:  Hiba J Mustafa; Henry L Wong; Mahmoud Al-Kofahi; Malinda Schaefer; Ashwin Karanam; Michael M Todd
Journal:  Obstet Gynecol       Date:  2020-07       Impact factor: 7.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.